Hunan Jiudian Pharmaceutical Co. Ltd. Class A

Hunan Jiudian Pharmaceutical Co. Ltd. Class A

SSZSE:300705
10.03
CNY
-0.08
(-0.79%)
0.59EPS
18.05P/E
5.54BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A carries a market capitalization of 5.54B, placing it among publicly traded companies globally. Its enterprise value stands at 5.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.54B
Enterprise Value5.68B

Important Dates

Hunan Jiudian Pharmaceutical Co. Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A has 500.29M shares outstanding.

Shares Outstanding500.29M

Valuation Ratios

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 18.05. The price-to-sales ratio is 1.91, and the price-to-book ratio stands at 2.07.

PE Ratio18.05
PS Ratio1.91
PB Ratio2.07
P/TBV Ratio2.74

Enterprise Valuation

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 15.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.68B versus a market cap of 5.54B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.96
EV / EBITDA15.40
EV / EBIT15.40

Financial Position

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.55, indicating elevated leverage, while an interest coverage ratio of 13.16 demonstrates strong ability to service its debt obligations.

Current Ratio2.43
Quick Ratio1.06
Debt / Equity26.55
Debt / EBITDA2.03
Interest Coverage13.16

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A posted a return on equity (ROE) of 11.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.73, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.34, useful for judging operating efficiency across full business cycles. The company generates approximately 1.26M in revenue per employee across its workforce of 2,298.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.41 indicates how many times Hunan Jiudian Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)11.64
Return on Assets (ROA)7.73
Return on Invested Capital (ROIC)9.19
Return on Capital Employed (ROCE)10.34
Revenue Per Employee1.26M
Employee Count2,298.00
Inventory Turnover2.41

Taxes

CNY

Over the twelve months ended September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A recorded 59.75M in income tax expense. That works out to an effective tax rate of 16.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 354.32M, leaving 306.36M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax59.75M
Effective Tax Rate16.86

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A's stock has declined approximately 40.37% over the past 52 weeks. The 50-day moving average sits at 10.65, while the 200-day moving average is 12.22.

52-Week Price Change-40.37%
50-Day Moving Average10.65
200-Day Moving Average12.22

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A generated 2.89B in revenue and converted that into 306.36M in net income, yielding earnings per share of 0.59. EBITDA reached 368.87M, while operating income came in at 431.27M.

Revenue2.89B
Gross Profit1.85B
Operating Income431.27M
Pretax Income354.32M
Net Income306.36M
EBITDA368.87M
EBIT368.87M
Earnings Per Share (EPS)0.59

Balance Sheet

CNY

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A holds 755.20M in cash and equivalents against 749.79M in total debt, resulting in a net debt position of 104.51M. Total book value stands at 2.68B, with working capital of 1.02B providing operational flexibility.

Cash & Cash Equivalents755.20M
Total Debt749.79M
Net Debt104.51M
Equity (Book Value)2.68B
Book Value Per Share5.35
Working Capital1.02B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-537.16M

Margins

Over the twelve months ended September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A posted a gross margin of 63.88, reflecting its pricing power and cost economics. The operating margin of 14.91 and net profit margin of 10.59 provide insight into operational efficiency.

Gross Margin63.88
Operating Margin14.91
Pretax Margin12.25
Profit Margin10.59
EBITDA Margin12.76

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A paid dividends of 0.42 per share. The dividend payout ratio of 73.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.80, meaning Hunan Jiudian Pharmaceutical Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.42
Payout Ratio73.95
Shareholder Yield-0.80

Stock Splits

Hunan Jiudian Pharmaceutical Co. Ltd. Class A's most recent stock split took place on May 24, 2024 with a 5:7 split ratio.

Last Split Date5/24/2024
Split Ratio5:7

Scores

As of September 30, 2026, Hunan Jiudian Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 4.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.19